144PClinical and treatment features associated with improved 5-year survival rate in ALK-positive lung cancer treated with ALK-TKIs. (13th April 2019) - Passaro, A; Prelaj, A; Spitaleri, G; Del Signore, E; Rossi, G; Guerini-Rocco, E; Barberis, M; Catania, C; de Marinis, F